Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Operating Margin (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Operating Margin for 13 consecutive years, with 80.05% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 12910.0% to 80.05% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4.16% through Dec 2025, up 6876.0% year-over-year, with the annual reading at 3.35% for FY2025, 6957.0% up from the prior year.
  • Operating Margin for Q4 2025 was 80.05% at Theravance Biopharma, up from 32.29% in the prior quarter.
  • The five-year high for Operating Margin was 80.05% in Q4 2025, with the low at 1540.08% in Q1 2022.
  • Average Operating Margin over 5 years is 232.39%, with a median of 101.98% recorded in 2024.
  • The sharpest move saw Operating Margin soared 424331bps in 2021, then tumbled -95165bps in 2022.
  • Over 5 years, Operating Margin stood at 375.8% in 2021, then soared by 68bps to 119.0% in 2022, then surged by 70bps to 35.53% in 2023, then tumbled by -38bps to 49.06% in 2024, then skyrocketed by 263bps to 80.05% in 2025.
  • According to Business Quant data, Operating Margin over the past three periods came in at 80.05%, 32.29%, and 10.4% for Q4 2025, Q3 2025, and Q2 2025 respectively.